Carl Zeiss Meditec Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Markus Weber
Chief executive officer
€1.1m
Total compensation
| CEO salary percentage | 40.8% |
| CEO tenure | 2.9yrs |
| CEO ownership | n/a |
| Management average tenure | 4.7yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Dec 04
Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk
Nov 19Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital
Sep 19Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Sep 06Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?
Aug 23At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?
Aug 09Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Jul 11Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled
Jun 10Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing
May 26Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 11Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
May 09Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?
Mar 24Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Mar 11Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement
Feb 12Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jan 29What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
Dec 08Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital
Nov 08Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price
Oct 24Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?
Sep 24Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?
Sep 08Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jul 24We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)
Jun 19Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?
Jun 06Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?
May 22Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price
Apr 19Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet
Feb 26Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 10Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Jan 28Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Jan 12Carl Zeiss Meditec (ETR:AFX) Will Pay A Larger Dividend Than Last Year At €1.10
Dec 29Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Dec 14What Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?
Nov 04Calculating The Intrinsic Value Of Carl Zeiss Meditec AG (ETR:AFX)
Oct 18Investors Will Want Carl Zeiss Meditec's (ETR:AFX) Growth In ROCE To Persist
Sep 12Carl Zeiss Meditec (ETR:AFX) Seems To Use Debt Rather Sparingly
Aug 25Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Hit The Brakes
May 30Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Feb 27Carl Zeiss Meditec's (ETR:AFX) Returns Have Hit A Wall
Feb 08Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Dec 12Carl Zeiss Meditec (ETR:AFX) Has Some Way To Go To Become A Multi-Bagger
Nov 06If You Like EPS Growth Then Check Out Carl Zeiss Meditec (ETR:AFX) Before It's Too Late
Sep 06Investors Met With Slowing Returns on Capital At Carl Zeiss Meditec (ETR:AFX)
Aug 08Here's Why We Think Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation Looks Fair for the time being
May 21Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems
May 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | €1m | €435k | €179m |
| Jun 30 2024 | n/a | n/a | €203m |
| Mar 31 2024 | n/a | n/a | €261m |
| Dec 31 2023 | n/a | n/a | €277m |
| Sep 30 2023 | €1m | €426k | €290m |
| Jun 30 2023 | n/a | n/a | €308m |
| Mar 31 2023 | n/a | n/a | €278m |
| Dec 31 2022 | n/a | n/a | €307m |
| Sep 30 2022 | €1m | €298k | €294m |
Compensation vs Market: Markus's total compensation ($USD1.12M) is below average for companies of similar size in the German market ($USD1.95M).
Compensation vs Earnings: Markus's compensation has been consistent with company performance over the past year.
CEO
Markus Weber
2.9yrs
Tenure
€1,067,100
Compensation
Dr. Markus Weber is CEO & Chairman of Management Board of Carl Zeiss Meditec AG from January 01, 2022 and served as its President since January 01, 2022 until December 2022. He joined ZEISS Semiconductor M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Management Board | 2.9yrs | €1.07m | no data | |
| CFO & Member of the Management Board | 6.2yrs | €784.50k | no data | |
| Head of Global Regulatory & Clinical Affairs | 1.9yrs | €22.50k | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Chief Human Resources Officer | no data | no data | no data | |
| Chief Medical Officer for Global Ophthalmic Devices | 8.2yrs | no data | no data | |
| Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec | 4.8yrs | no data | no data | |
| President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit | 4.6yrs | no data | no data | |
| Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technology | no data | no data | no data |
4.7yrs
Average Tenure
59yo
Average Age
Experienced Management: AFX's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Head of Global Regulatory & Clinical Affairs | 1.8yrs | €22.50k | no data | |
| Chairman of the Supervisory Board | 4.5yrs | no data | no data | |
| Honorary Chairman of the Supervisory Board | 3.6yrs | €43.10k | no data | |
| Member of the Supervisory Board | 4.5yrs | €36.00k | no data | |
| Member of the Supervisory Board | 3.6yrs | €55.00k | no data | |
| Employee Representative Member of the Supervisory Board | 1.8yrs | €24.50k | no data | |
| Member of the Supervisory Board | 6.7yrs | €43.10k | no data | |
| Employee Representative Deputy Chairman of Supervisory Board | 5.2yrs | €55.60k | no data | |
| Shareholder Representative Member of Supervisory Board | less than a year | no data | no data | |
| Employee Representative Member of Supervisory Board | 4.8yrs | €38.60k | no data | |
| Member of Supervisory Board | 3.6yrs | no data | no data | |
| Employee Representative Member of the Supervisory Board | 2.8yrs | €36.00k | no data |
3.6yrs
Average Tenure
52.5yo
Average Age
Experienced Board: AFX's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 18:37 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Carl Zeiss Meditec AG is covered by 32 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pierre-Yves Gauthier | AlphaValue |
| Samuel England | Berenberg |
| Scott Bardo | Berenberg |